

Human Immunoglobulin (pH4) for Intravenous Injection Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/H571FD003773EN.html>

Date: January 2020

Pages: 98

Price: US\$ 3,000.00 (Single User License)

ID: H571FD003773EN

Abstracts

SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Human Immunoglobulin (pH4) for Intravenous Injection market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Human Immunoglobulin (pH4) for Intravenous Injection market segmented into

5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

Based on the end-use, the global Human Immunoglobulin (pH4) for Intravenous Injection market classified into

Primary Immunodeficiency Disease

Immune-mediated Thrombocytopenia

Kawasaki Disease

B Chroniclymphocytic Leukemia(B-CLL)

Based on geography, the global Human Immunoglobulin (pH4) for Intravenous Injection market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Baxter

CSL

Bayer

Grifols

Octapharma

Shanghai RAAS

Hualan Biological

China Biologic

Tiantan Biologic

Shuanglin Bio-pharmacy

Sichuan Yuanda Shuyang

Boya Bio-pharmaceutical

Shanghai Institute of Biological

Contents

1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
 - 1.2.1 Product Type
 - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

2 GLOBAL HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION INDUSTRY

- 2.1 Summary about Human Immunoglobulin (pH4) for Intravenous Injection Industry
- 2.2 Human Immunoglobulin (pH4) for Intravenous Injection Market Trends
 - 2.2.1 Human Immunoglobulin (pH4) for Intravenous Injection Production & Consumption Trends
 - 2.2.2 Human Immunoglobulin (pH4) for Intravenous Injection Demand Structure Trends
- 2.3 Human Immunoglobulin (pH4) for Intravenous Injection Cost & Price

3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunity
 - 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
 - 4.1.1 North America (U.S., Canada and Mexico)
 - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
 - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
 - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

4.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

4.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Primary Immunodeficiency Disease

4.3.2 Immune-mediated Thrombocytopenia

4.3.3 Kawasaki Disease

4.3.4 B Chroniclymphocytic Leukemia(B-CLL)

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

5.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

5.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Primary Immunodeficiency Disease

5.3.2 Immune-mediated Thrombocytopenia

5.3.3 Kawasaki Disease

5.3.4 B Chroniclymphocytic Leukemia(B-CLL)

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

- 6.1.2 UK
- 6.1.3 France
- 6.1.4 Italy
- 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
 - 6.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 6.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 6.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
- 6.3 Consumption Segmentation (2017 to 2021f)
 - 6.3.1 Primary Immunodeficiency Disease
 - 6.3.2 Immune-mediated Thrombocytopenia
 - 6.3.3 Kawasaki Disease
 - 6.3.4 B Chroniclymphocytic Leukemia(B-CLL)
- 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

- 7.1 Region Segmentation (2017 to 2021f)
 - 7.1.1 China
 - 7.1.2 India
 - 7.1.3 Japan
 - 7.1.4 South Korea
 - 7.1.5 Southeast Asia
 - 7.1.6 Australia
 - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
 - 7.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 7.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 7.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
- 7.3 Consumption Segmentation (2017 to 2021f)
 - 7.3.1 Primary Immunodeficiency Disease
 - 7.3.2 Immune-mediated Thrombocytopenia
 - 7.3.3 Kawasaki Disease

- 7.3.4 B Chroniclymphocytic Leukemia(B-CLL)
- 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

- 8.1 Region Segmentation (2017 to 2021f)
 - 8.1.1 Brazil
 - 8.1.2 Argentina
 - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
 - 8.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 8.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 8.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
- 8.3 Consumption Segmentation (2017 to 2021f)
 - 8.3.1 Primary Immunodeficiency Disease
 - 8.3.2 Immune-mediated Thrombocytopenia
 - 8.3.3 Kawasaki Disease
 - 8.3.4 B Chroniclymphocytic Leukemia(B-CLL)
- 8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

- 9.1 Region Segmentation (2017 to 2021f)
 - 9.1.1 GCC
 - 9.1.2 North Africa
 - 9.1.3 South Africa
 - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
 - 9.2.1 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 9.2.2 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
 - 9.2.3 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection
- 9.3 Consumption Segmentation (2017 to 2021f)
 - 9.3.1 Primary Immunodeficiency Disease

- 9.3.2 Immune-mediated Thrombocytopenia
- 9.3.3 Kawasaki Disease
- 9.3.4 B Chroniclymphocytic Leukemia(B-CLL)
- 9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

- 10.1.1 Baxter
- 10.1.2 CSL
- 10.1.3 Bayer
- 10.1.4 Grifols
- 10.1.5 Octapharma
- 10.1.6 Shanghai RAAS
- 10.1.7 Hualan Biological
- 10.1.8 China Biologic
- 10.1.9 Tiantan Biologic
- 10.1.10 Shuanglin Bio-pharmacy
- 10.1.11 Sichuan Yuanda Shuyang
- 10.1.12 Boya Bio-pharmaceutical
- 10.1.13 Shanghai Institute of Biological

10.2 Human Immunoglobulin (pH4) for Intravenous Injection Sales Date of Major Players (2017-2020e)

- 10.2.1 Baxter
- 10.2.2 CSL
- 10.2.3 Bayer
- 10.2.4 Grifols
- 10.2.5 Octapharma
- 10.2.6 Shanghai RAAS
- 10.2.7 Hualan Biological
- 10.2.8 China Biologic
- 10.2.9 Tiantan Biologic
- 10.2.10 Shuanglin Bio-pharmacy
- 10.2.11 Sichuan Yuanda Shuyang
- 10.2.12 Boya Bio-pharmaceutical
- 10.2.13 Shanghai Institute of Biological

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

List Of Tables

LIST OF TABLES

1. Table Human Immunoglobulin (pH4) for Intravenous Injection Product Type Overview
2. Table Human Immunoglobulin (pH4) for Intravenous Injection Product Type Market Share List
3. Table Human Immunoglobulin (pH4) for Intravenous Injection Product Type of Major Players
4. Table Brief Introduction of Baxter
5. Table Brief Introduction of CSL
6. Table Brief Introduction of Bayer
7. Table Brief Introduction of Grifols
8. Table Brief Introduction of Octapharma
9. Table Brief Introduction of Shanghai RAAS
10. Table Brief Introduction of Hualan Biological
11. Table Brief Introduction of China Biologic
12. Table Brief Introduction of Tiantan Biologic
13. Table Brief Introduction of Shuanglin Bio-pharmacy
14. Table Brief Introduction of Sichuan Yuanda Shuyang
15. Table Brief Introduction of Boya Bio-pharmaceutical
16. Table Brief Introduction of Shanghai Institute of Biological
17. Table Products & Services of Baxter
18. Table Products & Services of CSL
19. Table Products & Services of Bayer
20. Table Products & Services of Grifols
21. Table Products & Services of Octapharma
22. Table Products & Services of Shanghai RAAS
23. Table Products & Services of Hualan Biological
24. Table Products & Services of China Biologic
25. Table Products & Services of Tiantan Biologic
26. Table Products & Services of Shuanglin Bio-pharmacy
27. Table Products & Services of Sichuan Yuanda Shuyang
28. Table Products & Services of Boya Bio-pharmaceutical
29. Table Products & Services of Shanghai Institute of Biological
30. Table Market Distribution of Major Players
31. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
32. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
33. Table Global Human Immunoglobulin (pH4) for Intravenous Injection Market Forecast (Million USD) by Region 2021f-2026f

34. Table Global Human Immunoglobulin (pH4) for Intravenous Injection Market Forecast (Million USD) Share by Region 2021f-2026f

35. Table Global Human Immunoglobulin (pH4) for Intravenous Injection Market Forecast (Million USD) by Demand 2021f-2026f

36. Table Global Human Immunoglobulin (pH4) for Intravenous Injection Market Forecast (Million USD) Share by Demand 2021f-2026f

List Of Figures

LIST OF FIGURES

1. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7. Figure Global Human Immunoglobulin (pH4) for Intravenous Injection Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10. Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11. Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13. Figure 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14. Figure 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15. Figure 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16. Figure Primary Immunodeficiency Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17. Figure Immune-mediated Thrombocytopenia Segmentation Market Size (USD

Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

18. Figure Kawasaki Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19. Figure B Chroniclymphocytic Leukemia(B-CLL) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

20. Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

21. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

22. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

23. Figure 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

24. Figure 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

25. Figure 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

26. Figure Primary Immunodeficiency Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

27. Figure Immune-mediated Thrombocytopenia Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

28. Figure Kawasaki Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

29. Figure B Chroniclymphocytic Leukemia(B-CLL) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

30. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

31. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

32. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

33. Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

34. Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

35. Figure 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for

Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

36. Figure 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

37. Figure 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

38. Figure Primary Immunodeficiency Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

39. Figure Immune-mediated Thrombocytopenia Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

40. Figure Kawasaki Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

41. Figure B Chronic lymphocytic Leukemia (B-CLL) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

42. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

43. Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

44. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

45. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

46. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

47. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

48. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

49. Figure 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

50. Figure 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

51. Figure 1.25g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

52. Figure Primary Immunodeficiency Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53. Figure Immune-mediated Thrombocytopenia Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54. Figure Kawasaki Disease Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55. Figure B Chroniclymphocytic Leukemia(B-CLL) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59. Figure 5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60. Figure 2.5g/Bottle Human Immunoglobulin (pH4) for Intravenous Injection (pH4) for Intravenous Injection Segmentation Market Size (USD Million) 2017-20

I would like to order

Product name: Human Immunoglobulin (pH4) for Intravenous Injection Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/H571FD003773EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H571FD003773EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

